# Effect of Dapagliflozin on VT in Patients With Heart Failure.

Study · id `cardio:ct-nct05550441` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05550441](<https://clinicaltrials.gov/study/NCT05550441>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05550441

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05550441. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-15 (anticipated); primary completion 2024-11-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05550441, source copy `cardio:ctgov-nct05550441-2022-09-22`, retrieved 2026-10-26)
- Planned start: 2022-11-15 (anticipated) (ClinicalTrials.gov record NCT05550441, source copy `cardio:ctgov-nct05550441-2022-09-22`, retrieved 2026-10-26)
- Primary completion: 2024-11-15 (anticipated) (ClinicalTrials.gov record NCT05550441, source copy `cardio:ctgov-nct05550441-2022-09-22`, retrieved 2026-10-26)
- Completion: 2024-11-15 (anticipated) (ClinicalTrials.gov record NCT05550441, source copy `cardio:ctgov-nct05550441-2022-09-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05550441-2022-09-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dapagliflozin on VT in Patients With Heart Failure.
- Condition: Heart Failure
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (`cardio:org-sun-yat-sen-memorial-hospital-of-sun-yat-sen-university`)

## Provenance

Content hash: ef8897eb6e3b1b0fef448733eb1d89b222b81c6e868a8aa459b79a1173076a8c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
